scholarly journals Pharmacogenomics of antidepressants for major depressive disorder

2012 ◽  
Vol 1 (9) ◽  
pp. 222-224 ◽  
Author(s):  
Joel Martin ◽  
Kelly C. Lee
Keyword(s):  
United States ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Treatment Options ◽  
The United States ◽  
Primary Treatment ◽  
Major Depressive ◽  
Current Guidelines

Major depressive disorder (MDD) is a common disorder, affecting approximately 10% of adults in the United States each year. The primary treatment options for moderate to severe MDD are antidepressant medications, mainly selective serotonin reuptake inhibitors (SSRIs). Current guidelines recommend an initial trial of 4–8 weeks to determine if a medication is effective for a patient. Through the use of pharmacogenomics, it may be possible to predict whether patients will respond to and tolerate SSRIs. This article discusses several genes and alleles that may play a role in a patient's response to SSRIs.

Use of a Second Generation Antipsychotic among Patients Diagnosed with Major Depressive Disorder in the United States

2012 ◽  
Vol 26 (4) ◽  
pp. 235-241
Author(s):  
David A. Sclar ◽  
Linda M. Robison ◽  
Lawrence J. Cohen ◽  
Kimberly K. Laubmeier ◽  
Iftekhar D. Kalsekar ◽  
...  
Keyword(s):  
United States ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Second Generation ◽  
The United States ◽  
Major Depressive ◽  
Second Generation Antipsychotic

Major Depressive Disorder and Insulin Resistance in Nondiabetic Young Adults in the United States: The National Health and Nutrition Examination Survey, 1999-2002

2010 ◽  
Vol 13 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Qiuhua Shen ◽  
Sandra Bergquist-Beringer ◽  
Valmi D. Sousa
Keyword(s):  
United States ◽  
Insulin Resistance ◽  
Young Adults ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
National Health ◽  
The United States ◽  
Nutrition Examination Survey ◽  
Major Depressive ◽  
Health And Nutrition

Objective: The association between depression and insulin resistance has been evaluated in previous studies with conflicting results. This study aimed to explore the relationship between major depressive disorder (MDD) and insulin resistance among nondiabetic young adult men and women in the United States. Method: Analyses of cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 1999—2002, were conducted. The nationally representative sample consisted of 279 men and 358 women aged 20—39 years. MDD was determined by the WHO Composite International Diagnostic Interview (CIDI). Insulin resistance was measured by the homeostasis model assessment for insulin resistance. Results: Of 637 subjects, 16 men and 18 women had MDD (weighted percentage = 6.6%, SE = 1.2). Using logistic regression, no significant association was found between MDD and insulin resistance among the nondiabetic young adults in bivariate analysis (β = -0.01, OR = 0.99, 95% CI = [0.38, 2.57], p = .98). A significant interaction effect between gender and MDD was observed. For men, MDD was negatively associated with insulin resistance after adjusting for age, race/ethnicity, waist circumference, smoking status, systolic blood pressure and triglyceride level (β = -2.12, OR = 0.12, 95% CI = [0.02, 0.62], p = .01). No significant association between MDD and insulin resistance among women was found (β = 0.61, OR = 1.84, 95% CI = [0.47, 7.14], p = .38). Conclusions: Overall findings suggest there is no significant association between MDD and insulin resistance among nondiabetic young adults aged 20—39 years. However, gender differences in this relationship were noted.

Sign in / Sign up

Export Citation Format

Share Document